ERBB2 and breast cancer: A recent study evaluating 21,807 advanced cancers, in which 16% were breast tumours, showed the utility of the liquid biopsy to detect targetable mutations in breast cancer patients, for example, alterations in PIK3CA, ESR1 and MYC, FGFR1, HER2 amplifications [89].